Soligenix (SNGX) Competitors $2.27 -0.06 (-2.58%) Closing price 03:59 PM EasternExtended Trading$2.27 0.00 (0.00%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. CARA, GRCE, CLDI, ALLK, FNCH, JATT, CVM, CYTH, LIAN, and CMMBShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Cara Therapeutics (CARA), Grace Therapeutics (GRCE), Calidi Biotherapeutics (CLDI), Allakos (ALLK), Finch Therapeutics Group (FNCH), JATT Acquisition (JATT), CEL-SCI (CVM), Cyclo Therapeutics (CYTH), LianBio (LIAN), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Cara Therapeutics Grace Therapeutics Calidi Biotherapeutics Allakos Finch Therapeutics Group JATT Acquisition CEL-SCI Cyclo Therapeutics LianBio Chemomab Therapeutics Soligenix (NASDAQ:SNGX) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings. Is SNGX or CARA more profitable? Cara Therapeutics has a net margin of -1,099.76% compared to Soligenix's net margin of -1,473.38%. Soligenix's return on equity of -223.29% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soligenix-1,473.38% -223.29% -74.18% Cara Therapeutics -1,099.76%-367.97%-107.43% Do insiders & institutionals have more ownership in SNGX or CARA? 3.6% of Soligenix shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 2.8% of Soligenix shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer SNGX or CARA? Cara Therapeutics received 389 more outperform votes than Soligenix when rated by MarketBeat users. However, 72.97% of users gave Soligenix an outperform vote while only 72.42% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformSoligenixOutperform Votes27872.97% Underperform Votes10327.03% Cara TherapeuticsOutperform Votes66772.42% Underperform Votes25427.58% Which has better earnings and valuation, SNGX or CARA? Soligenix has higher earnings, but lower revenue than Cara Therapeutics. Soligenix is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoligenix$840K6.78-$6.14M-$6.11-0.37Cara Therapeutics$7.14M3.45-$118.51M-$21.01-0.26 Does the media favor SNGX or CARA? In the previous week, Soligenix had 10 more articles in the media than Cara Therapeutics. MarketBeat recorded 11 mentions for Soligenix and 1 mentions for Cara Therapeutics. Cara Therapeutics' average media sentiment score of 1.87 beat Soligenix's score of -0.01 indicating that Cara Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Soligenix Neutral Cara Therapeutics Very Positive Do analysts rate SNGX or CARA? Cara Therapeutics has a consensus price target of $27.84, indicating a potential upside of 417.47%. Given Cara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cara Therapeutics is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soligenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, SNGX or CARA? Soligenix has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. SummaryCara Therapeutics beats Soligenix on 9 of the 17 factors compared between the two stocks. Remove Ads Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.70M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-0.307.2023.1319.03Price / Sales6.78226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.596.476.944.33Net Income-$6.14M$141.90M$3.20B$247.06M7 Day Performance-4.62%-3.05%-2.30%-0.52%1 Month Performance0.89%-4.63%3.10%-3.73%1 Year Performance-76.63%-8.61%11.22%1.74% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix1.3024 of 5 stars$2.27-2.6%N/A-75.3%$5.70M$840,000.00-0.3020Earnings ReportShort Interest ↓Analyst RevisionNews CoverageCARACara Therapeutics4.0091 of 5 stars$5.12-0.2%$27.84+443.8%-36.9%$23.42M$7.14M-0.2480Positive NewsGRCEGrace Therapeutics2.4736 of 5 stars$2.29+5.0%$12.00+424.0%N/A$23.22MN/A-1.97N/APositive NewsCLDICalidi Biotherapeutics1.6772 of 5 stars$0.87+2.2%$16.67+1,817.9%N/A$23.00M$50,000.000.0038News CoverageALLKAllakos4.6148 of 5 stars$0.25+2.8%$2.00+687.7%-82.1%$22.68MN/A-0.13190Short Interest ↓FNCHFinch Therapeutics GroupN/A$13.75+0.7%N/A+436.4%$22.08M$110,000.00-1.56190JATTJATT AcquisitionN/A$1.28+18.5%N/A-34.1%$22.08MN/A0.003High Trading VolumeCVMCEL-SCIN/A$0.28-6.5%N/A-87.2%$21.94MN/A-0.5943Gap UpHigh Trading VolumeCYTHCyclo Therapeutics2.9047 of 5 stars$0.66-5.6%$0.95+43.7%-50.2%$21.76M$870,725.00-0.739Upcoming EarningsShort Interest ↓News CoverageLIANLianBioN/A$0.20flatN/A-37.1%$21.61MN/A-0.25110Gap DownCMMBChemomab Therapeutics3.5495 of 5 stars$1.50+6.4%$9.00+500.0%+54.9%$21.54MN/A-1.5020Short Interest ↓News CoverageGap Up Remove Ads Related Companies and Tools Related Companies Cara Therapeutics Competitors Grace Therapeutics Competitors Calidi Biotherapeutics Competitors Allakos Competitors Finch Therapeutics Group Competitors JATT Acquisition Competitors CEL-SCI Competitors Cyclo Therapeutics Competitors LianBio Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNGX Stock Free SNGX Stock Alerts